Singapore's National Precision Medicine Programme

Precision Health Research, Singapore (PRECISE) is the national central entity coordinating Singapore's multi-phase National Precision Medicine (NPM) programme.

Established to drive a whole-of-Singapore effort, PRECISE works with research, clinical, and industry partners to generate insights into Asian genomics and translate these into better health outcomes and economic opportunities.

NPM Phase II sequenced 100,000 Singaporeans and conducted clinical implementation studies, linking genomic, lifestyle, and healthcare data to deepen understanding of Asian diseases. NPM Phase III, now underway is conducted in partnership with Singapore’s three healthcare clusters. Focusing on patient participants in clinical settings, Phase III will evaluate how genomics can be applied in practice to inform national health strategies, creating opportunities for innovation in diagnostics, therapeutics, and digital health.

PRECISE is a programme of the Consortium for Clinical Research and Innovation, Singapore (opens in new tab). NPM Phase II is supported by the National Research Foundation, Singapore (NRF) under the RIE2020 White Space (MOH-000588 and MOH-001264) and administered by the Singapore Ministry of Health (MOH) through the National Medical Research Council (NMRC) Office, MOH Holdings Pte Ltd. NPM Phase III is supported by the Singapore MOH through the NMRC Office, MOH Holdings Pte Ltd under the NMRC RIE2025 NPM Phase III Funding Initiative (MOH-001734).